ROCHESTER MEDICAL CORPORATION 
By STEWARTVILLE, Minn., Jan. 25, 2012 /PRNewswire/ -- Rochester Medical Corporation (NASDAQ:ROCM) today announced operating results for its first quarter ended December 31, 2011.
The Company reported sales of $13,846,000 for the current quarter compared to $10,946,000 for the first quarter of last year. It also reported net loss of $75,000 or ($.01) per diluted share compared to net loss of $169,000 or ($.01) per diluted share for the same quarter of last year.
The 26% increase in sales resulted from a 45% increase in Rochester Medical Direct Sales partially offset by a 20% decrease in Private Label Sales. The percentages were the same on a constant currency basis which assumes current exchange rates for all periods in order to exclude the impact of foreign exchange variations.
Net income adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or "Non-GAAP Net Income" for the current quarter was $285,000 or $.02 per diluted share compared to Non-GAAP Net Income of $377,000 or $.03 per diluted share for the first quarter of last year. The decrease for the current quarter was due to increased gross profit being more than offset by increased expenses primarily related to our expanded sales and marketing efforts.
Commenting on the first quarter, Rochester Medical's CEO and President Anthony J. Conway said, "Our organic Direct Sales are growing nicely, especially where we have our own dedicated sales and marketing personnel. Overall U.S. Direct Sales rose 27% over last year's first quarter with U.S. Acute Care sales rising 31% and U.S. Home Care sales growing at a 27% pace. These are strong numbers, and they reflect the increasing effectiveness of our U.S. Sales and Marketing team and the growing acceptance of our advanced catheter technology. The United Kingdom also reported strong 18% Direct Sales growth. The solid Direct Sales activities were offset by soft Private Label Sales which, as we have noted in the past, can fluctuate significantly in any given quarter due to the timing of orders. We believe that Private Label Sales for the full fiscal year remain on track. Direct Sales to International distributors were down somewhat compared to the same period last year. This too was due to timing of orders to some of our larger distributors, and we expect sales to those distributors to show growth for the full fiscal year. Overall I am pleased with our first quarter results, and we continue to expect strong Direct Sales growth and stable annualized Private Label Sales going forward."
Conference Call and Webcast
The Company will hold a quarterly conference call today to discuss its earnings report.
The call will begin at 3:30 p.m. central time (4:30 p.m. eastern time).
This call is being webcast by Thomson Reuters and can be accessed at Rochester Medical's website at www.rocm.com. To listen live to the conference call via telephone, call:
Domestic: 888.680.0865
International: 617.213.4853
Pass code: 76698813
https://www.theconferencingservice.com/prereg/
Preregistration: key.process?key=PUJTDK4BA
Replay will be available for seven days at www.rocm.com or via telephone at:
Domestic: 888 286.8010
International: 617 801.6888
Pass code: 23609340
Individual investors can listen to the call at www.fulldisclosure.com, Thomson Reuters individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
Forward-Looking Statements
This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the future financial and operating results of Rochester Medical. Such statements are based on currently available information, operating plans and management's expectations about future events and trends. Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, and our level of success in increasing Rochester Medical Direct Sales revenue, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of Private Label Sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2011, and reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
Rochester Medical has provided Non-GAAP Net Income (Loss) in addition to net income (loss) calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income (Loss) provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Similarly, constant currency represents reported sales with the cost/benefit of currency movements removed. Management uses the measure to understand the growth of the business on a constant dollar basis, as fluctuations in exchange rates can distort the underlying growth of the business both positively and negatively. While we recognize that foreign exchange volatility is a reality for a global company, we routinely review our Company performance on a constant dollar basis, and we believe this also allows our shareholders to understand better our Company's growth trends.
Non-GAAP Net Income (Loss) and constant currency are not measures of financial performance under GAAP, and should not be considered an alternative to net income or any other measure of performance or liquidity under GAAP. Non-GAAP Net Income (Loss) and constant currency are not comparable to information provided by other companies. Non-GAAP Net Income (Loss) and constant currency have limitations as analytical tools and should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP. Reconciliations of Net Loss and Non-GAAP Net Income (Loss), and reconciliations of sales under GAAP and sales on a constant currency basis, are presented at the end of this press release.
About Rochester Medical Corporation
Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company also sells certain ostomy and wound and scar care products and other brands of urological products into the European marketplace.
For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600 or Parice Halbert, CFA, at Westwicke Partners (443) 213-0500. More information about Rochester Medical is available on its website at http://www.rocm.com.
ROCHESTER MEDICAL CORPORATION
Reconciliation of Reported GAAP Net Income to Non-GAAP
Net Income
For the Three months ended
December 31, 2011 and 2010
(unaudited)
Three months ended
December 31,
------------
2011 2010
---- ----
GAAP Net Loss as Reported $(75,000) $(169,000)
======== =========
Loss Per Share as Reported $(0.01) $(0.01)
====== ======
Adjustments for non-recurring
unusual items:
Recruitment costs for
additional US sales force (1) - 132,000
Merger and acquisition costs
for Laprolan B.V. (2) - 90,000
--- ------
Subtotal - 222,000
Adjustments for recurring non-
cash expenses:
Intangible amortization (3) 158,000 129,000
ASC 718 compensation expense
(4) 202,000 195,000
------- -------
Subtotal 360,000 324,000
Non-GAAP Net Income $285,000 $377,000
======== ========
Non-GAAP Diluted EPS $0.02 $0.03
===== =====
Weighted Average Shares -
Diluted 12,311,866 12,605,122
(1) Costs associated with recruitment firm to locate and
hire 34 additional sales staff in the US. The gross
amount
of recruiting costs are $200,500 net of taxes of $68,500
for a net amount of $132,000.
(2) Merger and acquisition related expenses net of taxes
pertaining to the agreement to purchase Laprolan B.V.
The gross amount of acquisition costs are $136,000 net of
taxes of $46,000 for a net amount of $90,000.
(3) Amortization of the intangibles acquired in June 2006
asset acquisition from Coloplast AS and Mentor
Corporation and the intangibles acquired in the January
2011 acquisition of Laprolan from Fornix N.V.
Management believes these assets are appreciating. This
adjustment adds back amortization
expense for the three months ended December 31, 2011 and
2010 related to certain intangibles.
The gross amount of amortization expense for the three
months ended December 31, 2011 and 2010 is
$218,000 and $163,000 net of taxes of $60,000 and $34,000 for net amounts of $158,000 and $129,000
respectively.
(4) Compensation expense mandated by ASC 718. This
adjustment adds back the compensation expense
recorded for stock options granted to employees and
directors that vested during the three months ended
December 31, 2011 and 2010. The gross amount of
compensation expense for the three months ended
December 31, 2011 and 2010 is $316,000 and $295,000 net of
taxes of $114,000 and $100,000 for net amounts of
$202,000 and $195,000 respectively.
Condensed Balance Sheets
(unaudited)
September
December 31, 30,
2011 2011
---- ----
Assets
Current Assets
Cash and equivalents $8,337,578 $8,722,935
Marketable securities 25,218,950 26,182,308
Accounts receivable 8,455,770 8,644,332
Inventories 11,670,635 11,278,694
Prepaid expenses and other
assets 1,663,245 1,361,259
Deferred income tax asset 1,992,998 1,618,495
--------- ---------
Total current assets 57,339,176 57,808,023
Property and equipment, net 12,171,612 12,052,685
Deferred income tax asset 1,167,763 1,242,010
Intangible assets, net 9,860,980 10,272,671
Goodwill 9,569,190 9,764,075
--------- ---------
Total Assets $90,108,721 $91,139,464
=========== ===========
Liabilities and Stockholders'
Equity
Current liabilities:
Accounts payable $2,651,057 $2,773,398
Accrued expenses 2,546,604 2,961,270
Short-term debt 18,330,905 17,862,185
---------- ----------
Total current liabilities 23,528,566 23,596,853
Long-term liabilities 1,806,711 1,565,764
Stockholders' equity 64,773,444 65,976,847
---------- ----------
Total Liabilities and
Stockholder Equity $90,108,721 $91,139,464
=========== ===========
Summary Statements Of Operations
(unaudited)
Three months ended
December 31,
------------
2011 2010
---- ----
Sales $13,845,666 $10,946,405
Cost of sales 6,877,193 5,542,274
--------- ---------
Gross profit 6,968,473 5,404,131
Gross profit % 50.3% 49.4%
Costs and expense:
Marketing and selling 4,504,120 3,881,980
Research and development 376,269 277,855
General and administrative 2,108,813 1,709,093
--------- ---------
Total operating expenses 6,989,202 5,868,928
--------- ---------
Loss from operations (20,729) (464,797)
Other income (expense)
Interest income 9,735 52,570
Interest expense (81,150) (31,259)
Other expense (19,655) (16,282)
------- -------
Net loss before income taxes (111,799) (459,768)
Income tax benefit (36,452) (290,686)
------- --------
Net loss $(75,347) $(169,082)
======== =========
Net loss per common share -
Basic $(0.01) $(0.01)
====== ======
Net loss per common share -
Diluted $(0.01) $(0.01)
====== ======
Weighted Average Shares:
Basic 12,136,125 12,127,268
========== ==========
Weighted Average Shares:
Diluted 12,136,125 12,127,268
========== ==========
ROCHESTER MEDICAL CORPORATION
Reconciliation of Reported GAAP Revenue to Non-GAAP Revenue in
Constant Currency
For the Three months ended
December 31, 2011 and 2010
(unaudited)
Three months ended
December 31,
------------
2011 2010
---- ----
GAAP Sales as Reported $13,845,666 $10,946,405
=========== ===========
Exchange rate as Reported 1.57 1.58
==== ====
Constant Currency Sales $13,845,666 $10,923,574
=========== ===========
(1) Exchange rate used for Constant
Currency Purposes 1.57 1.57
==== ====
Net Effect of Constant Currency Illustration $- $(22,831)
=== ========
(1) For illustrative purposes constant currency translates prior
period foreign sales at current exchange rates.
For Rochester Medical Corporation this is the conversion rate of
pound sterling to US dollars. The rate represents
the average exchange rate for the respective three month period.
SOURCE Rochester Medical Corporation
